Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Dynavax Technologies Corp. (DVAX)
NASDAQ:DVAX
Holding DVAX?
Track your performance easily
Earnings Data
Report Date
Feb 20, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
$0.04Last Year’s EPS
$0Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2024
|% Change Since: 5.82%
|Next Earnings Date:Feb 20, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance, record sales of HEPLISAV-B, and strategic initiatives like the share repurchase plan. However, there were notable challenges with the discontinuation of the Tdap program and FDA hurdles. Overall, the sentiment leans positive due to the financial achievements and future growth prospects.Company Guidance
During the Dynavax Technologies Q3 2024 earnings call, the company provided comprehensive guidance on its financial and strategic trajectory. Key metrics included HEPLISAV-B's record-breaking net product sales of $79 million, contributing to Dynavax's ongoing profitability. The company anticipates HEPLISAV-B's U.S. market opportunity to expand to over $900 million by 2030, with a market share target of at least 60%. The gross margin for HEPLISAV-B improved to 84% in Q3 and is expected to remain around 80% for the year. Dynavax also announced a $200 million share repurchase plan, underscoring its robust financial position and commitment to shareholder value. Additionally, the company detailed advancements in its clinical pipeline, including the Z-1018 shingles vaccine, with Phase I/II trial results expected in the second half of 2025, and ongoing discussions with the FDA regarding HEPLISAV-B's label expansion for dialysis patients. The guidance reflects Dynavax's strategic focus on market expansion, disciplined capital allocation, and continued investment in growth opportunities.HEPLISAV-B Record Sales
HEPLISAV-B achieved over $79 million in net product revenue, with a market share increase to 44% compared to 41% last year. Retail Pharmacy segment market share increased to 55% and IDN market share to 56%.
Financial Performance and Guidance
Dynavax reported quarterly net income of $18 million, with HEPLISAV-B net sales guidance for 2024 narrowed to $265 million to $270 million, representing over 25% year-over-year growth. Gross margin improved to 84% in Q3.
Share Repurchase Program
A $200 million share repurchase plan was authorized by the Board of Directors, indicating confidence in the company's financial strength.
Z-1018 Shingles Vaccine Program
Active enrollment in Phase I/II trial with expected completion by end of 2024 and top line data in the second half of 2025.
---
DVAX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
DVAX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $12.02 | $13.01 | +8.24% |
| Aug 06, 2024 | $10.05 | $10.75 | +6.97% |
| May 08, 2024 | $11.65 | $11.01 | -5.49% |
| Feb 22, 2024 | $12.44 | $12.75 | +2.49% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Dynavax Technologies Corp. (DVAX) report earnings?
Dynavax Technologies Corp. (DVAX) is schdueled to report earning on Feb 20, 2025, TBA Not Confirmed.
What is Dynavax Technologies Corp. (DVAX) earnings time?
Dynavax Technologies Corp. (DVAX) earnings time is at Feb 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is DVAX EPS forecast?
DVAX EPS forecast for the fiscal quarter 2024 (Q4) is $0.04.
---